Current Good Tissue Practice (cGTP): Understanding FDA Quality Requirements for HCT/Ps
Current Good Tissue Practice (cGTP) is one of the foundational regulatory concepts governing the manufacture of many Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Although healthcare professionals frequently encounter the term when reviewing supplier documentation, its purpose is often misunderstood.
Some assume that compliance with Current Good Tissue Practice means a product has been approved by the U.S. Food and Drug Administration or that it guarantees product quality or clinical performance. In reality, cGTP serves a different purpose within the regulatory framework established under 21 CFR Part 1271.
Current Good Tissue Practice establishes requirements governing how certain HCT/Ps are recovered, processed, stored, labeled, packaged, distributed, and documented. These requirements are intended to help reduce the risk of communicable disease transmission while promoting consistency, documentation integrity, and operational control throughout the tissue lifecycle.
Throughout this guide you'll learn what Current Good Tissue Practice is, why it exists, how it relates to donor eligibility, quality systems, FDA Establishment Registration, documentation, and traceability, and why cGTP should not be confused with FDA approval.
Understanding Current Good Tissue Practice (cGTP)
Current Good Tissue Practice is best understood as the quality framework supporting many HCT/Ps regulated under Section 361 of the Public Health Service Act. Rather than evaluating products for clinical effectiveness, cGTP establishes manufacturing, documentation, and operational requirements intended to promote consistent handling of HCT/Ps.
On This Page
What Is Current Good Tissue Practice (cGTP)?
Current Good Tissue Practice (cGTP) refers to the quality-related requirements established by the U.S. Food and Drug Administration for certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). These requirements are codified primarily within 21 CFR Part 1271 Subpart D and establish standards intended to help prevent the introduction, transmission, and spread of communicable diseases during the manufacture of HCT/Ps.
Unlike regulations that evaluate whether a medical product is safe or effective for a particular clinical use, Current Good Tissue Practice focuses on how an HCT/P is handled throughout its lifecycle. It establishes documented expectations for recovery, processing, storage, labeling, packaging, distribution, environmental controls, personnel training, recordkeeping, and quality oversight.
Current Good Tissue Practice should be viewed as the operational quality framework supporting many HCT/Ps regulated solely under Section 361 of the Public Health Service Act. It provides consistency in manufacturing practices while supporting documentation integrity and regulatory oversight.
Why Current Good Tissue Practice Exists
Congress authorized the FDA to establish regulatory safeguards intended to reduce the risk of communicable disease transmission associated with Human Cells, Tissues, and Cellular and Tissue-Based Products. Current Good Tissue Practice provides many of the operational requirements that help achieve this objective.
Rather than focusing on clinical outcomes, cGTP focuses on operational consistency. By establishing requirements for documented procedures, environmental controls, personnel qualifications, equipment maintenance, recordkeeping, and quality oversight, the regulation promotes standardized manufacturing practices across regulated activities.
For licensed healthcare professionals reviewing supplier documentation, understanding the purpose of cGTP helps place manufacturing documentation into its proper regulatory context. Current Good Tissue Practice explains how regulated activities are expected to be controlled—it is not intended to determine whether a product is clinically appropriate for a particular patient or procedure.
Primary Objectives of cGTP
- Reduce the risk of communicable disease transmission.
- Promote consistent manufacturing practices.
- Establish documented operating procedures.
- Support product traceability throughout the tissue lifecycle.
- Promote accurate documentation and record retention.
- Provide a framework for FDA regulatory oversight.
These objectives work together to support regulatory consistency while providing healthcare professionals with greater confidence that documented manufacturing practices are performed within an established quality framework.
Major Components of Current Good Tissue Practice
Current Good Tissue Practice is not a single requirement. It is a collection of interconnected quality principles that govern multiple aspects of HCT/P manufacturing and documentation. Each component contributes to the broader quality framework established under 21 CFR Part 1271.
Facilities and Environmental Controls
Facilities should be designed and maintained to support appropriate recovery, processing, storage, and handling of HCT/Ps. Environmental controls help minimize conditions that could adversely affect product integrity or increase the risk of contamination.
Equipment and Supplies
Equipment used during manufacturing should be appropriately maintained, inspected, cleaned, and, where applicable, calibrated according to documented procedures. Supplies used during manufacturing should be suitable for their intended purpose and incorporated into documented quality processes.
Personnel Training
Individuals performing regulated activities should receive appropriate training for the responsibilities they perform. Documented training helps support operational consistency while ensuring personnel understand applicable procedures and quality requirements.
Documented Procedures
Standard Operating Procedures (SOPs) provide written instructions describing how regulated activities are performed. These procedures help promote consistency between personnel, reduce unnecessary variation, and support documentation integrity throughout manufacturing operations.
Recordkeeping
Current Good Tissue Practice places significant emphasis on documentation. Records provide objective evidence that procedures were followed, equipment was maintained, required activities were completed, and quality-related events were appropriately documented throughout the HCT/P lifecycle.
Relationship Between cGTP and Quality Systems
Current Good Tissue Practice (cGTP) and quality systems are closely related, but they are not identical concepts. While cGTP establishes regulatory requirements for manufacturing operations involving certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), a quality system represents the broader organizational framework used to implement, document, monitor, and continually improve those activities.
In practical terms, cGTP defines many of the regulatory expectations, while a quality system provides the documented processes, personnel responsibilities, oversight activities, and operational controls necessary to consistently meet those expectations.
Understanding this distinction helps healthcare professionals interpret supplier documentation more accurately. Documentation describing a quality system often demonstrates how an organization manages its operations, whereas cGTP establishes what regulatory requirements apply to those operations.
How cGTP Supports Quality Systems
- Establishes documented operating procedures.
- Supports consistent manufacturing practices.
- Promotes personnel qualification and training.
- Requires documentation and record retention.
- Supports quality monitoring and continual oversight.
- Strengthens traceability throughout the HCT/P lifecycle.
For a more comprehensive discussion of quality management concepts, visit our HCT/P Quality Systems Guide.
Documentation and Traceability Under cGTP
One of the defining characteristics of Current Good Tissue Practice is its emphasis on documentation. Nearly every activity performed during the manufacture of an HCT/P generates records that contribute to a documented history of the product's lifecycle. These records provide objective evidence that established procedures were followed and support regulatory transparency.
Documentation extends beyond simple recordkeeping. It creates continuity between donor evaluation, recovery, processing, storage, labeling, packaging, distribution, and final disposition. This continuity allows healthcare professionals, manufacturers, and regulatory agencies to understand how an HCT/P has been managed throughout its lifecycle.
Examples of Documentation Maintained Under cGTP
- Standard Operating Procedures (SOPs)
- Personnel training records
- Equipment maintenance documentation
- Environmental monitoring records
- Processing documentation
- Storage and temperature monitoring records
- Distribution records
- Complaint investigations
- Corrective action documentation
- Record retention files
Together, these documents support product traceability and help establish a transparent record describing how regulated activities were performed. Documentation also allows organizations to investigate deviations, evaluate complaints, and demonstrate adherence to established procedures when appropriate.
Relationship to Other Regulatory Concepts
Current Good Tissue Practice is only one component of the broader regulatory framework governing many Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). Healthcare professionals should understand how cGTP connects with other regulatory concepts discussed throughout the Not By Chance Life Knowledge Center.
| Regulatory Topic | Relationship to cGTP |
|---|---|
| 21 CFR Part 1271 | Provides the overall regulatory framework governing many HCT/Ps. |
| Section 361 | Provides statutory authority for many HCT/P regulatory requirements. |
| FDA Establishment Registration | Identifies certain regulated establishments but does not replace cGTP requirements. |
| Donor Eligibility | Works alongside cGTP to reduce the risk of communicable disease transmission. |
| Minimal Manipulation | Represents a separate regulatory criterion used when evaluating certain HCT/Ps. |
| Homologous Use | Defines another important regulatory concept distinct from manufacturing requirements. |
| Quality Systems | Provides the broader operational framework supporting implementation of cGTP. |
Together, these regulatory concepts create an interconnected framework that helps healthcare professionals understand how HCT/Ps are recovered, processed, documented, and regulated.
Common Misconceptions About Current Good Tissue Practice
Misconception #1 — cGTP Means FDA Approval
Current Good Tissue Practice establishes manufacturing requirements. It does not represent FDA approval, clearance, certification, or endorsement of a product.
Misconception #2 — cGTP Guarantees Product Quality
Compliance with cGTP establishes regulatory manufacturing expectations but should not be interpreted as a guarantee of product performance, clinical outcomes, or suitability for any specific patient.
Misconception #3 — cGTP Applies Only to Laboratories
Current Good Tissue Practice applies to regulated manufacturing activities involving HCT/Ps and extends beyond laboratory testing to include recovery, processing, storage, labeling, packaging, distribution, documentation, and quality oversight where applicable.
Misconception #4 — cGTP Replaces Supplier Evaluation
Healthcare professionals should continue reviewing supplier documentation, donor eligibility information, quality systems, traceability records, and other supporting documentation. Current Good Tissue Practice represents one important component of a comprehensive documentation review.
Applying Current Good Tissue Practice During Supplier Evaluation
For licensed healthcare professionals, Current Good Tissue Practice (cGTP) should be viewed as one component of a broader regulatory and documentation review rather than as a stand-alone indicator of quality. While cGTP establishes manufacturing and documentation requirements for certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), meaningful supplier evaluation requires consideration of multiple regulatory concepts working together.
When reviewing supplier documentation, healthcare professionals should understand both what cGTP demonstrates and what remains outside the scope of cGTP requirements.
Questions cGTP Helps Answer
- Are documented manufacturing procedures established?
- Are quality-related activities supported by written documentation?
- Are traceability and recordkeeping procedures maintained?
- Are personnel training and operational controls incorporated into the quality framework?
- Does the documentation describe manufacturing safeguards intended to reduce communicable disease transmission?
Questions cGTP Does Not Answer
- Has the FDA approved this HCT/P?
- Has the FDA determined the product is clinically effective?
- Does cGTP guarantee manufacturing quality?
- Does compliance with cGTP establish superiority over another manufacturer?
- Can cGTP replace independent supplier evaluation?
Frequently Asked Questions
What is Current Good Tissue Practice (cGTP)?
Current Good Tissue Practice (cGTP) establishes FDA requirements governing how certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) are recovered, processed, stored, labeled, packaged, distributed, and documented under 21 CFR Part 1271.
Does cGTP mean an HCT/P is FDA approved?
No. Current Good Tissue Practice establishes manufacturing and documentation requirements. It should not be interpreted as FDA approval, clearance, certification, endorsement, or a determination regarding product safety or effectiveness.
Why is documentation emphasized throughout cGTP?
Documentation provides objective evidence that regulated activities were performed according to established procedures. Accurate documentation supports traceability, quality oversight, record retention, and regulatory transparency.
How does cGTP relate to donor eligibility?
Current Good Tissue Practice and donor eligibility address different regulatory requirements that work together within the HCT/P framework. Donor eligibility focuses on donor screening, testing, and relevant medical records, while cGTP establishes manufacturing and operational requirements.
Does cGTP apply only to laboratories?
No. Current Good Tissue Practice applies to a wide range of regulated manufacturing activities involving HCT/Ps, including recovery, processing, storage, labeling, packaging, distribution, documentation, and quality oversight where applicable.
Can healthcare professionals verify cGTP compliance from one document?
No single document demonstrates the complete implementation of Current Good Tissue Practice. Healthcare professionals should review the broader documentation package together with supplier quality systems, donor eligibility records, traceability documentation, and other supporting regulatory information.
Why is cGTP important for healthcare professionals?
Understanding Current Good Tissue Practice helps healthcare professionals interpret manufacturing documentation within its proper regulatory context and better understand how quality-related activities support the handling of HCT/Ps.
Documentation and Regulatory Education
Licensed healthcare professionals seeking additional educational resources regarding Current Good Tissue Practice, regulatory documentation, supplier evaluation, or HCT/P quality systems are welcome to contact Not By Chance Life.
Our educational resources are designed to support documentation literacy, regulatory understanding, and informed review of HCT/P documentation.
Credential verification is required before provider-specific educational materials are made available.
Request Regulatory Information
This information is provided for educational purposes only. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. For use by licensed medical professionals.Educational Disclaimer
This guide is intended solely to explain Current Good Tissue Practice (cGTP) within the regulatory framework governing Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). It should not be interpreted as legal advice, regulatory advice, or an official FDA interpretation.
Current Good Tissue Practice establishes manufacturing and documentation requirements intended to support regulatory oversight and reduce the risk of communicable disease transmission. It should not be interpreted as FDA approval, product endorsement, or evidence of clinical safety or effectiveness.
Healthcare professionals should consult applicable federal regulations, official FDA guidance, and independent professional judgment when evaluating HCT/P documentation.